The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Non-Expert Acquisition & Remote Expert Review of Screening Echocardiography Images From Child Health & AnteNatal Clinics (NEARER SCAN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06002243
Recruitment Status : Not yet recruiting
First Posted : August 21, 2023
Last Update Posted : March 18, 2024
Sponsor:
Collaborators:
The University of Western Australia
Telethon Kids Institute
Western Australian Country Health Service
Northern Territory Government of Australia
Timor-Leste Ministry of Health
Miwatj Health Aboriginal Corporation
Mala'la Health Service Aboriginal Corporation
Pilbara Aboriginal Health Alliance
Information provided by (Responsible Party):
Joshua Francis, Menzies School of Health Research

Brief Summary:
The Non-Expert Acquisition and Remote Expert Review of Screening echocardiography images from Child health and AnteNatal clinics (NEARER SCAN) study is a co-designed, implementation research project that will improve equitable access to culturally safe, best quality care for Rheumatic Heart Disease (RHD) in high-burden Aboriginal and Torres Strait Islander communities in Australia, and in Timor-Leste. The research addresses an area of unmet need, using novel technologies and embedding them in health practice, to enhance and accelerate diagnosis of RHD outside acute health settings and improve outcomes. The study will be conducted in partnership with community leaders and local partners.

Condition or disease Intervention/treatment Phase
Rheumatic Heart Disease Diagnostic Test: SPLASH echocardiography screening Not Applicable

Detailed Description:

This study titled 'Non-Expert Acquisition and Remote Expert Review of Screening echocardiography images from Child health and AnteNatal clinics' (NEARER SCAN; "LENO BESIK" in Tetum) aims to co-design, implement and evaluate a task-sharing approach to echocardiographic screening for early detection and management of rheumatic heart disease (RHD) in high-risk settings in Australia and Timor-Leste.

Specific objectives include:

  1. To co-design implementation strategies with communities underpinned by local program theories.
  2. To implement SPLASH echocardiography training and a task-sharing approach to echocardiographic screening for early detection and management of RHD in communities, based on co-designed implementation strategies.
  3. To conduct a realist evaluation to understand what implementation strategies assist in integrating this intervention into routine health service delivery and why.
  4. To determine the clinical effectiveness of the intervention in terms of impact on key clinical outcome measures.
  5. To conduct cost-of-illness, cost-effectiveness and budget-impact analyses of the task-sharing approach to echocardiographic screening for early detection and management of RHD in Australia and Timor-Leste.

Local primary health clinic staff will be trained to perform focused echocardiography using hand-carried ultrasound (HCU) devices employing the 'Single Parasternal Long Axis view with a Sweep of the Heart' (SPLASH) technique. The acquired images will be interpreted by experts (cardiologists and cardiac sonographers) remotely from the site of acquisition. Approximately 1500 children and pregnant women will be screened across high-risk communities in Australia and Timor Leste, over an 18 month period.

A mixed-methods effectiveness-implementation study design will be used to evaluate the implementation of an intervention designed to achieve early detection and management of RHD in high-risk populations. An implementation strategy will be co-designed at each site with the local community and participating primary healthcare (PHC) service, incorporating non-adaptable elements of the intervention, and mapped onto a Theory of Change framework. Co-design, implementation and evaluation will occur simultaneously, and a Type 2 hybrid design study will be used to evaluate both the implementation strategies and the clinical effectiveness of the intervention. The clinical effectiveness will be assessed as the change in the proportion of the at-risk population that received secondary prophylaxis by the end of the study compared to baseline. Program implementation will be evaluated with a realist evaluation to explain under what circumstances the program is successfully integrated into routine service delivery. Data informing evaluation will include numbers of normal, abnormal, and uninterpretable SPLASH echocardiograms obtained, numbers of participants progressing through the cascade of care, augmented by qualitative data from interviews conducted with staff and participants, and costs.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1500 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Non-Expert Acquisition and Remote Expert Review of Screening Echocardiography Images From Child Health and AnteNatal Clinics (NEARER SCAN)
Estimated Study Start Date : April 2024
Estimated Primary Completion Date : June 2025
Estimated Study Completion Date : December 2025


Arm Intervention/treatment
Experimental: Intervention
Participant receiving echocardiography screening.
Diagnostic Test: SPLASH echocardiography screening
Screening echocardiogram performed by a briefly trained health worker with images reviewed off site by an expert cardiologist or cardiac sonographer to determine screening outcome. Screening outcome may include: screen positive, screen negative or uninterpretable images.




Primary Outcome Measures :
  1. Change in proportion receiving secondary antibiotic prophylaxis [ Time Frame: 18 months from commencement of study ]
    The change in proportion of the at-risk population receiving secondary antibiotic prophylaxis at the end of the study as compared to baseline


Secondary Outcome Measures :
  1. Full echocardiogram following screening echocardiogram [ Time Frame: 3 months from screening echocardiogram ]
    Proportion of people with an abnormal or uninterpretable screening echocardiogram who get a full diagnostic echocardiogram within 3 months and receive a diagnosis.

  2. Proportion of people diagnosed with RHD who are retained in care [ Time Frame: 18 months from commencement of study ]
    Proportion of people diagnosed during study period with RHD who receive guideline-based care by local health service

  3. Secondary antibiotic prophylaxis prescription and adherence [ Time Frame: 12 months from time of diagnosis or at end of the study (which ever is longer). ]
    Proportion of people prescribed secondary prophylaxis who are achieving >= 80% adherence in a 12 months period from time of diagnosis or the end of the study, whichever is longer.

  4. Maternal morbidity and mortality outcomes [ Time Frame: Within 6 weeks of the individual's post-partum period ]
    Description of maternal morbidity and mortality in pregnant women diagnosed with RHD on echocardiographic screening. This will be reported in absolute numbers and percentage of study population. Morbidity will include cardiac complications (heart failure, arrhythmia, aborted sudden cardiac death, acute myocardial infarction), need for obstetric intervention including emergency cesarean section, intensive care admission, other obstetric complications.

  5. Prevalence of rheumatic heart disease within the screened population [ Time Frame: 18 months from commencement of study ]
    Prevalence of RHD in screened population based on echocardiographic diagnosis

  6. Rheumatic valvular heart disease severity (mild, moderate or severe) within the screening population based on echocardiographic diagnosis [ Time Frame: 18 months from commencement of study ]
    Description of severity of RHD in screened population. This will include proportions of mild, moderate and severe valve disease.

  7. Neonatal morbidity and mortality outcomes [ Time Frame: Within 6 weeks post-partum ]
    Description of neonatal morbidity and mortality outcomes for the pregnant women diagnosed with RHD. This will be reported as absolute numbers and percentage of study population. Morbidity will include need for admission to neonatal intensive care.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   5 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria in Australia:

  • Any child between the age of 5 - 20 years old living in the participating community
  • Pregnant women at high risk for RHD undergoing antenatal appointments or a hospital admission will be invited to participate. High risk for RHD will be defined as being from an area where RHD all-age prevalence is >1/1000 RHD or acute rheumatic fever incidence >30/100,000 per year in 5-14-year-olds. For practical purposes, this means Aboriginal women living in urban, rural or remote communities in northern Australia, or immigrants from high-risk settings.

Inclusion criteria for Timor-Leste:

  • Any child between the age of 5-20 years old and any pregnant woman.

Exclusion criteria for Australia and Timor-Leste:

  • Women who are unable to consent due to physical, mental, or intellectual disability will be excluded. Women and children with known existing cardiac disease will NOT be excluded since evaluation of severity and change in severity during pregnancy will be tracked, and data will inform the calculation of prevalence.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06002243


Contacts
Layout table for location contacts
Contact: Joshua R Francis, MBBS +61423528381 josh.francis@menzies.edu.au
Contact: James A Marangou, MBBS +61412277527 james.marangou@menzies.edu.au

Sponsors and Collaborators
Menzies School of Health Research
The University of Western Australia
Telethon Kids Institute
Western Australian Country Health Service
Northern Territory Government of Australia
Timor-Leste Ministry of Health
Miwatj Health Aboriginal Corporation
Mala'la Health Service Aboriginal Corporation
Pilbara Aboriginal Health Alliance
Investigators
Layout table for investigator information
Principal Investigator: Joshua R Francis, MBBS Menzies School of Health Research
Layout table for additonal information
Responsible Party: Joshua Francis, Senior Research Fellow, Menzies School of Health Research
ClinicalTrials.gov Identifier: NCT06002243    
Other Study ID Numbers: APP2015869
First Posted: August 21, 2023    Key Record Dates
Last Update Posted: March 18, 2024
Last Verified: March 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Joshua Francis, Menzies School of Health Research:
Echocardiography
Task-sharing
Aboriginal and Torres Strait Islander Peoples
Pregnancy
Children
First Nation Peoples
Additional relevant MeSH terms:
Layout table for MeSH terms
Rheumatic Heart Disease
Heart Diseases
Cardiovascular Diseases
Rheumatic Fever
Streptococcal Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Bacterial Infections and Mycoses
Infections